Dr Jonathan Paul (PhD, BBiotech) is Co-Director of the Mothers and Babies Research Program and is dedicated to preventing preterm birth. In this regard, Dr Paul led the development of uterine-targeted nanoparticles as a novel targeted drug delivery system for the pregnant uterus. Dr Paul is further recognised for having identified a class of compounds capable of preventing the pro-labour phenotypic transformation of pregnant human uterine smooth muscle cells.
Dr Paul is the Lead Investigator (CIA) and team leader on numerous project grants and has been awarded >$7 million in competitive research funding, including a 2024 NHMRC Investigator grant, a 2022 NHMRC Ideas grant, a 2021 NHMRC Ideas grant, and a 2021 NSW Ministry of Health Gene and Cell Therapies Early-Mid Career Researcher Grant.
Dr Paul has been an Invited Speaker for The International Conference on Emerging Advanced Nanomaterials 2024 & 2020 (Newcastle), The Preterm Birth Therapeutics Symposium 2023 (Brisbane), The Society for Reproductive Investigation 2021 (Boston) & 2020 (Vancouver), The Society of Maternal-Fetal Medicine 2019 (Las Vegas), The Mercy Perinatal Australian Reproduction Update 2018 (Melbourne), the Australian Society for Medical Research 2018 (Newcastle), and The Society for Reproductive Biology 2017 (Perth).
Dr Paul has published original research, reviews, and chapters in leading journals, including Nature Communications, Trends in Endocrinology & Metabolism, and the American Journal of Obstetrics and Gynecology, the top-ranked Obstetrics journal that publishes original research.
